These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37573674)

  • 1. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.
    Mouabbi JA; Raghavendra AS; Bassett RL; Christgen M; Middleton L; Teshome M; Nasrazadani A; Hortobagyi G; Hassan A; Tripathy D; Layman RM
    Eur J Cancer; 2023 Sep; 191():113250. PubMed ID: 37573674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Coexisting Lobular Carcinoma In Situ With Invasive Lobular Carcinoma.
    Harbhajanka A; Lamzabi I; Syed S; Jain R; Ghai R; Reddy VB; Bitterman P; Gattuso P
    Appl Immunohistochem Mol Morphol; 2016; 24(10):738-743. PubMed ID: 26574630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pathologic Finding of Combined Lobular Carcinoma
    Jean-Louis CJ; Masdon J; Smith B; Battles O; Dale P
    Am Surg; 2017 May; 83(5):482-485. PubMed ID: 28541858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
    Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
    Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synchronous lobular carcinoma in situ and invasive lobular cancer: marker or precursor for invasive lobular carcinoma.
    Wallace AS; Xiang D; Hockman L; Arya M; Jeffress J; Wang Z; Dale PS
    Eur J Surg Oncol; 2014 Oct; 40(10):1245-9. PubMed ID: 24857380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic predisposition to in situ and invasive lobular carcinoma of the breast.
    Sawyer E; Roylance R; Petridis C; Brook MN; Nowinski S; Papouli E; Fletcher O; Pinder S; Hanby A; Kohut K; Gorman P; Caneppele M; Peto J; Dos Santos Silva I; Johnson N; Swann R; Dwek M; Perkins KA; Gillett C; Houlston R; Ross G; De Ieso P; Southey MC; Hopper JL; Provenzano E; Apicella C; Wesseling J; Cornelissen S; Keeman R; Fasching PA; Jud SM; Ekici AB; Beckmann MW; Kerin MJ; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Guénel P; Truong T; Laurent-Puig P; Kerbrat P; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Milne RL; Perez JI; Menéndez P; Benitez J; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Meindl A; Lichtner P; Schmutzler RK; Lochmann M; Brauch H; Fischer HP; Ko YD; ; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Dörk T; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Chenevix-Trench G; ; Lambrechts D; Weltens C; Van Limbergen E; Hatse S; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Radice P; Peterlongo P; Bonanni B; Volorio S; Giles GG; Severi G; Baglietto L; McLean CA; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Simard J; Goldberg MS; Labrèche F; Dumont M; Kristensen V; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Andrulis IL; Knight JA; Glendon G; Mulligan AM; Devillee P; Tollenaar RA; Seynaeve CM; Kriege M; Figueroa J; Chanock SJ; Sherman ME; Hooning MJ; Hollestelle A; van den Ouweland AM; van Deurzen CH; Li J; Czene K; Humphreys K; Cox A; Cross SS; Reed MW; Shah M; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Swerdlow A; Ashworth A; Orr N; Schoemaker M; Couch FJ; Hallberg E; González-Neira A; Pita G; Alonso MR; Tessier DC; Vincent D; Bacot F; Bolla MK; Wang Q; Dennis J; Michailidou K; Dunning AM; Hall P; Easton D; Pharoah P; Schmidt MK; Tomlinson I; Garcia-Closas M
    PLoS Genet; 2014 Apr; 10(4):e1004285. PubMed ID: 24743323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer].
    Aulmann S; Penzel R; Schirmacher P; Sinn HP
    Verh Dtsch Ges Pathol; 2007; 91():208-13. PubMed ID: 18314616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction.
    Nayar R; Zhuang Z; Merino MJ; Silverberg SG
    Hum Pathol; 1997 Mar; 28(3):277-82. PubMed ID: 9042790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
    Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
    Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
    Lien HC; Chen YL; Juang YL; Jeng YM
    Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation.
    Sasson AR; Fowble B; Hanlon AL; Torosian MH; Freedman G; Boraas M; Sigurdson ER; Hoffman JP; Eisenberg BL; Patchefsky A
    Cancer; 2001 May; 91(10):1862-9. PubMed ID: 11346867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleomorphic and Florid Lobular Carcinoma In Situ Variants of the Breast: A Clinicopathologic Study of 85 Cases With and Without Invasive Carcinoma From a Single Academic Center.
    Shamir ER; Chen YY; Chu T; Pekmezci M; Rabban JT; Krings G
    Am J Surg Pathol; 2019 Mar; 43(3):399-408. PubMed ID: 30489319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.
    Sakr RA; Schizas M; Carniello JV; Ng CK; Piscuoglio S; Giri D; Andrade VP; De Brot M; Lim RS; Towers R; Weigelt B; Reis-Filho JS; King TA
    Mol Oncol; 2016 Feb; 10(2):360-70. PubMed ID: 26643573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.
    De Brot M; Koslow Mautner S; Muhsen S; Andrade VP; Mamtani A; Murray M; Giri D; Sakr RA; Brogi E; King TA
    Breast Cancer Res Treat; 2017 Sep; 165(2):411-420. PubMed ID: 28612228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.
    Andrade VP; Morrogh M; Qin LX; Olvera N; Giri D; Muhsen S; Sakr RA; Schizas M; Ng CK; Arroyo CD; Brogi E; Viale A; Morrow M; Reis-Filho JS; King TA
    Mol Oncol; 2015 Apr; 9(4):772-82. PubMed ID: 25601220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer.
    Aulmann S; Penzel R; Longerich T; Funke B; Schirmacher P; Sinn HP
    Breast Cancer Res Treat; 2008 Feb; 107(3):331-5. PubMed ID: 17380381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.
    Giricz O; Reynolds PA; Ramnauth A; Liu C; Wang T; Stead L; Childs G; Rohan T; Shapiro N; Fineberg S; Kenny PA; Loudig O
    J Pathol; 2012 Jan; 226(1):108-19. PubMed ID: 21953071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.
    Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M
    Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.
    Vincent-Salomon A; Hajage D; Rouquette A; Cédenot A; Gruel N; Alran S; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Kirova Y
    Breast; 2012 Jun; 21(3):380-3. PubMed ID: 22531230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.